Psilocybin as a treatment for major depression
Psilocybin as a treatment for major depression
批准号:
MR/J00460X/1
负责人:
David Nutt
金额:
$64.78万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --
中文摘要
该项目的目的是测试裸盖菇素作为治疗重度抑郁症的疗效。裸盖菇素是一种天然存在的化合物,存在于某些种类的蘑菇中。它在结构上类似于大脑神经递质5-羟色胺--它与情绪有关(低大脑5-羟色胺水平与情绪低落有关)。几个世纪以来,裸盖菇素一直被用于精神治疗,最近还被用于心理治疗。现代研究表明,单独接触裸盖菇素可以改善一年以上的心理健康,并在长达6个月的时间内减轻抑郁症状,没有任何不良事件。利用脑功能成像(FMRI)和静脉注射裸盖菇素,我们最近发现大脑变化可以解释裸盖菇素的这些积极情绪效应。在这里,我们提出了一个有效的、安慰剂对照的设计来研究裸盖菇素作为治疗重度抑郁症的疗效。我们将招募44名重度抑郁症患者,他们将被随机分配到安慰剂组或裸盖菇素组。无论是患者还是研究人员都不知道哪些患者属于哪一组(双盲)。裸盖菇素可能对那些难以坚持慢性治疗计划的患者特别有益,因为它只需接触一次就可能有效。它也可能对持有严格悲观态度的患者特别有益,因为心理学和神经生物学数据表明,它针对的是与习惯性负面思维有关的大脑机制。
英文摘要
The aim of this project is to test the efficacy of psilocybin as a treatment for major depression. Psilocybin is a naturally occurring compound that is found in some species of mushroom. It is structurally similar to the brain neurotransmitter serotonin - which is implicated in mood (low brain serotonin levels are associated with low mood). Psilocybin has been used for centuries in spiritual healing contexts, and more recently in psychotherapy. Modern research has shown that single exposures to psilocybin can improve psychological well-being for over 1 year and decrease symptoms of depression for up to 6 months, without any adverse events. Using functional brain imaging (fMRI) and intravenous psilocybin, we recently found brain changes that can explain these positive mood effects of psilocybin. Here we propose a well powered, placebo-controlled design to study the efficacy of psilocybin as a treatment for major depression. We will recruit 44 patients with major depression that will be randomly allocated to either a placebo group or a psilocybin group. Neither the patients, nor the research staff will know which patients are in which group ('double-blind'). Psilocybin may be particularly beneficial for patients that struggle to adhere to chronic treatment schedules, as it is potentially effective after just one exposure. It may also be particularly beneficial for patients that hold rigidly pessimistic attitudes, since psychological and neurobiological data suggest that it targets brain mechanisms involved in habitual negative thinking.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fpsyg.2014.00255
发表时间:
2014
期刊:
Frontiers in psychology
影响因子:
3.8
作者:
[Carhart-Harris R, Nutt D]
通讯作者:
Nutt D
DOI:
10.1016/s2215-0366(16)30065-7
发表时间:
2016-07-01
期刊:
LANCET PSYCHIATRY
影响因子:
64.3
作者:
[Carhart-Harris, Robin L., Bolstridge, Mark, Nutt, David J.]
通讯作者:
Nutt, David J.
DOI:
10.1007/s00213-017-4771-x
发表时间:
2018-03
期刊:
Psychopharmacology
影响因子:
3.4
作者:
[Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ]
通讯作者:
Nutt DJ
DOI:
10.1016/j.biopsych.2013.12.015
发表时间:
2015-10-15
期刊:
Biological psychiatry
影响因子:
10.6
作者:
[Carhart-Harris RL, Murphy K, Leech R, Erritzoe D, Wall MB, Ferguson B, Williams LT, Roseman L, Brugger S, De Meer I, Tanner M, Tyacke R, Wolff K, Sethi A, Bloomfield MA, Williams TM, Bolstridge M, Stewart L, Morgan C, Newbould RD, Feilding A, Curran HV, Nutt DJ]
通讯作者:
Nutt DJ
Do appetitive gut hormones attenuate core behavioural components of addiction to prevent relapse in nicotine and alcohol addiction?
-
批准号:MR/M007022/1
-
项目类别:Research Grant
-
资助金额:$238.02万
-
财政年份:2014
-
负责人:David Nutt
-
依托单位:
Can enhancing SWS improve daytime function in patients with CFS?
-
批准号:MR/M501591/1
-
项目类别:Research Grant
-
资助金额:$15.78万
-
财政年份:2014
-
负责人:David Nutt
-
依托单位:
MICA: [11C]BU99008 - A novel Positron Emission Tomography ligand for the Imidazoline2 Binding Site, First in human and initial patient group
-
批准号:MR/L01307X/1
-
项目类别:Research Grant
-
资助金额:$79.94万
-
财政年份:2014
-
负责人:David Nutt
-
依托单位:
MICA: SRC inhibitors as potential antipsychotics: human testing with psilocybin
-
批准号:MR/K015192/1
-
项目类别:Research Grant
-
资助金额:$32.11万
-
财政年份:2013
-
负责人:David Nutt
-
依托单位:
Can enhancing SWS improve daytime function in patients with CFS?
-
批准号:MR/J002852/1
-
项目类别:Research Grant
-
资助金额:$17.23万
-
财政年份:2012
-
负责人:David Nutt
-
依托单位:
Neurotransmitters in Opiate and Alcohol Addiction
-
批准号:G1002226-E01/1
-
项目类别:Research Grant
-
资助金额:$203.68万
-
财政年份:2011
-
负责人:David Nutt
-
依托单位:
New drugs for addiction: focus on attenuating core behavioural components of heroin, cocaine and alcohol addiction
-
批准号:G1000018/1
-
项目类别:Research Grant
-
资助金额:$205.81万
-
财政年份:2011
-
负责人:David Nutt
-
依托单位:
PET imaging of human brain gliosis using Imidazoline2 (I2) binding sites: potential biomarker for Alzheimer's disease
-
批准号:G0801501/1
-
项目类别:Research Grant
-
资助金额:$60.01万
-
财政年份:2009
-
负责人:David Nutt
-
依托单位:
PET imaging of human brain a2-adrenoceptors and noradrenaline release: biomarkers for brain diseases; Focus depression
-
批准号:G0601461/1
-
项目类别:Research Grant
-
资助金额:$46.36万
-
财政年份:2007
-
负责人:David Nutt
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
-
批准号:82371144
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:汪雪玲
-
依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
-
批准号:82371251
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:肖勤
-
依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
-
批准号:82371997
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张春富
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
基于仿生矿化法构建氢离子捕获的炎症调节性水凝胶微球在卒中治疗中的研究
-
批准号:82372120
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮慧瞳
-
依托单位:
MICA基因及其抗体在肾移植排斥反应中的作用机制与干预策略研究
-
批准号:30872530
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2008
-
负责人:侯建全
-
依托单位: